Randomized Open Investigation Determining Steroid Dose — ROIDS-Dose  

Covid19 Clinical Trial

Official title: Randomized Open Investigation Determining Steroid Dose (ROIDS-Dose)

Status Completed

Clinical Trial Summary

Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.

Clinical Trial Description

Treatment for COVID-19 patients with respiratory failure has been vexing, but the use of steroids has shown promise. In a recent randomized control trial, dexamethasone 6 mg once daily showed a modest decrease in mortality among hospitalized COVID-19 patients who require oxygen supplementation or invasive mechanical ventilation. Other trials have shown that the inflammatory response to COVID-19 can be further attenuated at higher dosages of dexamethasone. These higher dosages have not been well studied and have not been directly compared to the current standard dose of dexamethasone 6 mg daily. We propose that a higher dexamethasone dose, equivalent to methylprednisolone 1 mg/kg/day which is routinely used to treat other inflammatory conditions of the lungs, may be more effective than the current standard dose in reducing mortality in COVID-19 patients with respiratory failure. ;

Related Conditions & MeSH terms

• COVID-19
• Covid19

• NCT number: NCT04834375
• Study type: Interventional
• Source: Northwell Health
• Status: Completed
• Phase: Phase 3
• Start date: March 19, 2021
• Completion date: March 29, 2022